Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	22.73K -	23.91K 5.16%						194K -	558K 187.63%	759K 36.02%	849K 11.86%
gross profit	-22.73K -	-23.91K 5.16%						-194K -	-558K 187.63%	-759K 36.02%	-849K 11.86%
selling and marketing expenses											-849K -
general and administrative expenses	22.34K -	1.28M 5,638.33%	6.09M 374.88%	7.96M 30.80%	9.65M 21.20%	16.10M 66.78%	19.65M 22.10%	31.50M 60.29%	46.54M 47.73%	47.05M 1.11%	50.57M 7.47%
selling general and administrative expenses	22.34K -	1.28M 5,638.33%	6.09M 374.88%	7.96M 30.80%	9.65M 21.20%	16.10M 66.78%	19.65M 22.10%	31.50M 60.29%	46.54M 47.73%	47.05M 1.11%	49.72M 5.67%
research and development expenses		656K -	17.78M 2,609.91%	20.40M 14.78%	26.43M 29.51%	46.79M 77.05%	47.83M 2.22%	60.40M 26.28%	84.72M 40.27%	92.81M 9.55%	115.23M 24.16%
other expenses		2.00M -	1.24M 37.88%	807K 34.92%	643K 20.32%	2.44M 278.85%	4.34M 78.12%	2.27M 47.59%	792K 65.17%	4.03M 408.21%
cost and expenses	22.34K -	3.93M 17,508.88%	23.86M 506.63%	28.37M 18.86%	36.08M 27.18%	62.88M 74.30%	67.48M 7.31%	91.90M 36.19%	131.26M 42.83%	139.87M 6.56%	165.80M 18.55%
operating expenses	22.34K -	3.93M 17,508.88%	23.86M 506.63%	28.37M 18.86%	36.08M 27.18%	62.88M 74.30%	67.48M 7.31%	91.90M 36.19%	131.26M 42.83%	139.87M 6.56%	164.96M 17.94%
interest expense	4.97K -	5.88K 18.15%	88K 1,397.36%	577K 555.68%	888K 53.90%	970K 9.23%	580K 40.21%	578K 0.34%	414K 28.37%	229K 44.69%	1.55M 576.42%
ebitda	-22.34K -	-3.66M 16,300.89%	-23.86M 551.32%	-28.37M 18.86%	-36.08M 27.18%	-62.88M 74.30%	-67.48M 7.31%	-91.90M 36.19%	-131.26M 42.83%	-139.87M 6.56%	-164.96M 17.94%
operating income	-22.34K -	-3.93M 17,508.88%	-23.86M 506.63%	-28.37M 18.86%	-36.08M 27.18%	-62.88M 74.30%	-67.48M 7.31%	-92.09M 36.48%	-131.82M 43.13%	-140.62M 6.68%	-165.80M 17.91%
depreciation and amortization		1K -	20K 1,900%	31K 55.00%	30K 3.23%	10K 66.67%	10 99.90%	194K 1,939,900%	558K 187.63%	759K 36.02%	849K 11.86%
total other income expenses net	-4.97K -	263K 5,387.49%	1.24M 371.48%	807K 34.92%	643K 20.32%	2.44M 278.85%	4.34M 78.12%	2.47M 43.12%	1.35M 45.30%	4.78M 254.37%	13.17M 175.36%
income before tax	-27.32K -	-3.67M 13,339.50%	-22.63M 516.32%	-27.56M 21.81%	-35.43M 28.57%	-60.45M 70.59%	-63.14M 4.46%	-89.63M 41.95%	-130.47M 45.57%	-135.84M 4.12%	-152.63M 12.36%
income tax expense		268.88K -	-20K 107.44%	-31K 55.00%	-30K 3.23%	3.41M 11,453.33%	-10 100.00%	-194K 1,939,900%	-558K 187.63%	229K 141.04%
net income	-27.32K -	-3.67M 13,339.50%	-22.63M 516.32%	-27.56M 21.81%	-35.43M 28.57%	-60.45M 70.59%	-63.14M 4.46%	-89.43M 41.64%	-129.91M 45.26%	-136.07M 4.74%	-152.63M 12.17%
weighted average shs out	5M -	14.51M 190.16%	9.93M 31.54%	18.70M 88.27%	23.24M 24.26%	35.19M 51.44%	41.95M 19.20%	53.08M 26.54%	66.35M 25.01%	66.99M 0.96%	73.23M 9.31%
weighted average shs out dil	5M -	14.51M 190.16%	9.93M 31.54%	18.70M 88.27%	23.24M 24.26%	35.19M 51.44%	41.95M 19.20%	53.08M 26.54%	66.35M 25.01%	66.99M 0.96%	73.23M 9.31%
eps	-0.01 -	-0.25 4,445.45%	-2.28 812.00%	-1.47 35.53%	-1.52 3.40%	-1.72 13.16%	-1.51 12.21%	-1.68 11.26%	-1.96 16.67%	-2.03 3.57%	-2.08 2.46%
epsdiluted	-0.01 -	-0.25 4,445.45%	-2.28 812.00%	-1.47 35.53%	-1.52 3.40%	-1.72 13.16%	-1.51 12.21%	-1.68 11.26%	-1.96 16.67%	-2.03 3.57%	-2.08 2.46%

NASDAQ:KURA

Kura Oncology, Inc.

Last Close

20.78

26/07 20:00

Market Cap

1.55B

Beta: 0.89

Volume Today

438.42K

Avg: 604.17K

PE Ratio

−11.43

PFCF: −13.14

Preview